Analysis of the pattern and course of juvenile idiopathic arthritis in children of the Samara Region

DOI: https://doi.org/10.29296/25877305-2021-03-10
Download full text PDF
Issue: 
3
Year: 
2021

E. Amosova, Candidate of Medical Sciences; S. Plakhotnikova, Candidate of Medical Sciences;
Professor G. Santalova, MD; Professor E. Borodulina*, MD; M. Davydova Samara State Medical University,
Ministry of Health of Russia

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and one of the most frequent childhood chronic diseases. Patients with continuous disease progression (33 to 75%) and insufficient efficiency of various types of basic therapy are currently prevalent in the pattern of JIA. It is important for the physician to predict the outcomes of the disease and to determine the clinical predictors of a long-term adverse JIA outcome. Objective. To study the pattern and course of JIA in children living in the Samara Region to optimize approaches to therapy. Subjects and methods. The gender and age characteristics of patients with JIA were studied. The diagnosis was verified according to the ILAR criteria. The pattern of JIA in the Samara Region was presented. The authors analyzed risk factors for, the mean age at onset of JIA in various types of its course, the involvement of different joints in the pathological process, the activity of JIA, X-ray characteristics and functional class in the most common variants, as well as concomitant diseases. Biological therapy, the mean duration of biological agent (BA) use and the mean age of patients receiving the treatment were analyzed. Results. The presented information on the pattern and course of JIA in the Samara Region, the time of diagnosis and the timing of prescribed therapy, including that with BAs, and the reasons for their discontinuation allow us to apply a differentiated approach to therapy and to evaluate its efficiency and safety.
Keywords: 
pediatrics
rheumatology
juvenile idiopathic arthritis
types of juvenile idiopathic arthritis
diagnosis
treatment

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Baranov A.A., Alekseeva E.I. Juvenil'nyj artrit. Detskaja revmatologija. Klinicheskie rekomendatsii dlja pediatrov. M.: Pediatr', 2013; 117 s. [Baranov A.A., Alekseeva E.I. Yuvenil’nyi artrit. Detskaya revmatologiya. Klinicheskie rekomendatsii dlya pediatrov. M.: Pediatr»», 2013; 117 s. (in Russ.)].
  2. Smolen J.S., Landewé R., Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76 (6): 960–77. DOI: 10.1136/annrheumdis-2016-210715
  3. Horneff G. Treatment options with biologics for juvenile idiopathic arthritis. Int J Clin Rheumatol. 2011; 6 (3): 1–19.
  4. Santalova G.V., Borodulina E.A., Kudlaj D.A. i dr. Revmaticheskie zabolevanija i tuberkuleznaja infektsija u detej i vzroslyh. Tuberkulez i bolezni legkih. 2019; 97 (2): 50–5 [Santalova G.V., Borodulina E.A., Kudlay D.A. et al. Rheumatic diseases and tuberculosis infection in children and adults. Tuberculosis and Lung Diseases. 2019; 97 (2): 50–5 (in Russ.)]. https://doi.org/10.21292/2075-1230-2019-97-2-50-55
  5. Bhatt K.H., Karjodkar F.R., Sansare K. et al. Juvenile idiopathic arthritis. Contemp Clin Dent. 2014; 5: 89–91. DOI: 10.4103/0976-237X.128677
  6. Giancane G., Consolaro A., Lanni S. et al. Juvenile Idiopathic Arthritis: Diagnosis and Treatment. Rheumatol Ther. 2016; 3 (2): 187–207. DOI: 10.1007/s40744-016-0040-4
  7. Alekseeva E.I. Juvenil'nyj idiopaticheskij artrit: klinicheskaja kartina, diagnostika, lechenie. Voprosy sovremennoj pediatrii. 2015; 14 (1): 78–94 [Alexeeva E.I. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Current Pediatrics. 2015; 14 (1): 78–94 (in Russ.)]. https://doi.org/10.15690/vsp.v14i1.1266
  8. Savost'janov K.V., Alekseeva E.I., Chistjakov D.A. Assotsiatsija genov, ne kodirujuschih komponenty glavnogo kompleksa gistosovmestimosti, s juvenil'nym idiopaticheskim artritom. Vestnik RAMN. 2014; 9–10: 83–94 [Savost’anov K.V., Alexeeva E.I., Chistiakov D.A. Contribution OF Non-HLA Genes to Juvenile Idiopathic Arthritis Susceptibility. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annals of the Russian Academy of Medical Sciences. 2014; 9–10: 83–94 (in Russ.)].
  9. Fedorov E.S., Krylov M.Ju., Salugina S.O. i dr. Polimorfizmy STAT4 rs7574865 G/T i IRF5 rs2004640 G/T kak markery predraspolozhennosti k juvenil'nomu idiopaticheskomu artritu. Chto mozhet dat' genetika dlja ponimanija ego geterogennosti? Sovremennaja revmatologija. 2019; 13 (4): 55–60 [Fedorov E.S., Krylov M.Yu., Salugina S.O. et al. STAT4 rs7574865 G/T and IRF5 rs2004640 G/T polymorphisms as markers of predisposition to juvenile idiopathic arthritis. What can genetics give to understand its heterogeneity? Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2019; 13 (4): 55–60 (in Russ.)]. DOI: 10/14412/1996-7012-2019-4-55-60
  10. Oen K., Malleson P. N., Cabral D. A. et al. Early predictors of longterm outcome in patients with JRA: subset-specific correlations. J Rheumatol. 2003; 30: 585–93.
  11. Nasonov E.L. Problemy immunopatologii revmatoidnogo artrita: evoljutsija bolezni. Nauchno-prakticheskaja revmatologija. 2017; 55 (3): 277–94 [Nasonov E.L. Problems of rheumatoid arthritis immunopathology: evolution of the disease. Rheumatology Science and Practice. 2017; 55 (3): 277–94 (in Russ.)]. https://doi.org/10.14412/1995-4484-2017-277-294
  12. Davydova M.A. Razvitie i prognoz destruktivnyh izmenenij sustavov u detej s juvenil'nym idiopaticheskim artritom. Voprosy prakticheskoj pediatrii. 2017; 12 (3): 46–53 [Davydova M.A. Development and prognosis of destructive changes of the joints in children with juvenile idiopathic arthritis. Vopr prakt pediatr = Clinical Practice in Pediatrics. 2017; 12 (3): 46–53 (in Russ.)]. DOI: 10.20953/1817-7646-2017-3-46-53
  13. Alekseeva E.I. Juvenil'nyj idiopaticheskij artrit: klinicheskaja kartina, diagnostika, lechenie. Voprosy sovremennoj pediatrii. 2015; 14 (1): 78–94 [Alexeeva E.I. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Current Pediatrics. 2015; 14 (1): 78–94 (in Russ.)]. https://doi.org/10.15690/vsp.v14i1.1266
  14. Kaleda M.I., Nikishina I.P., Kostareva O.M. Optimizatsija shem lechenija sistemnogo varianta juvenil'nogo artrita s korrektsiej rezhimov vnutrivennogo vvedenija totsilizumaba po dannym nabljudatel'nogo retrospektivnogo issledovanija. Nauchno-prakticheskaja revmatologija. 2019; 2: 229–34 [Kaleda M.I., Nikishina I.P., Kostareva O.M. Optimization of systemic juvenile arthritis treatment regimens with correction of tocilizumab intravenous administration according to data of observational retrospective study. Rheumatology Science and Practice. 2019; 57 (2): 229–34 (in Russ.)]. https://doi.org/10.14412/1995-4484-2019-229-234
  15. Alekseeva E.I., Valieva S.I., Bzarova T.M. i dr. Klinicheskij sluchaj primenenija totsilizumaba u patsienta s sistemnym juvenil'nym idiopaticheskim artritom. Pediatricheskaja farmakologija. 2016; 13 (4): 390–4 [Alekseeva E.I., Valieva S.I., Bzarova T.M. et al. Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case. Pediatric pharmacology. 2016; 13 (4): 390–4 (in Russ.)]. https://doi.org/10.15690/pf.v13i4.1613
  16. Chizhevskaja I., Beljaeva L. Terapija juvenil'nogo idiopaticheskogo artrita totsilizumabom. Nauka i innovatsii. 2019; 2 (192): 76–81 [Chyzheuskaya I., Belyaeva L. Therapy for juvenile idiopathic arthritis with tocilizumab. The Science and Innovations. 2019; 2 (192): 76–81 (in Russ.)]. https://doi.org/10.29235/1818-9857-2019-2-76-81
  17. Borodulina E.A., Santalova G.V., Kudlaj D.A. i dr. Monitoring tuberkuleznoj infektsii u detej s juvenil'nym idiopaticheskim artritom, poluchajuschih genno-inzhenernye preparaty. Pediatrija. Zhurnal im. G.N. Speranskogo. 2019; 98 (2): 209–13 [Borodulina E.A., Santalova G.V., Kudlay D.A. E.A. et al. Monitoring of tuberculosis infection in children with juvenile idiopathic arthritis receiving genetically preparations. Pediatria. 2019; 98 (2): 209–13 (in Russ.)]. DOI: 10.24110/0031-403X-2019-98-2-209-213